Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Many hematopoietic cell types express CD1d and are capable of presenting glycolipid antigens to invariant natural killer T cells (iNKT cells). However, the question of which cells are the principal presenters of glycolipid antigens in vivo remains controversial, and it has been suggested that this might vary depending on the structure of a particular glycolipid antigen. Here we have shown that a single type of cell, the CD8α(+) DEC-205(+) dendritic cell, was mainly responsible for capturing and presenting a variety of different glycolipid antigens, including multiple forms of α-galactosylceramide that stimulate widely divergent cytokine responses. After glycolipid presentation, these dendritic cells rapidly altered their expression of various costimulatory and coinhibitory molecules in a manner that was dependent on the structure of the antigen. These findings show flexibility in the outcome of two-way communication between CD8α(+) dendritic cells and iNKT cells, providing a mechanism for biasing toward either proinflammatory or anti-inflammatory responses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895174PMC
http://dx.doi.org/10.1016/j.immuni.2013.12.004DOI Listing

Publication Analysis

Top Keywords

glycolipid antigens
16
dendritic cells
12
natural killer
8
cells inkt
8
inkt cells
8
cells
7
glycolipid
6
single subset
4
dendritic
4
subset dendritic
4

Similar Publications

Background: Disialoganglioside (GD2) is a tumor-associated antigen that is highly expressed in various neuroectodermal cancers, including melanoma. While chimeric antigen receptor (CAR) T-cell immunotherapy has demonstrated remarkable success in treating hematologic neoplasms, the identification of suitable targets remains a major obstacle in translating this approach to solid tumors.

Methods: Peripheral blood T lymphocytes from six healthy donors were used to generate GD2-specific CAR T cells via retroviral transduction.

View Article and Find Full Text PDF

Sphingomyelin (SM) is primarily located in the outer leaflet of the plasma membrane. It plays a crucial role in intercellular communication and the morphology of neuronal cells by influencing the localization and function of various proteins. However, the mechanisms regulating the SM content in the neuronal plasma membrane remain largely elusive.

View Article and Find Full Text PDF

Objectives: We investigated the prevalence of anti-phenolic glycolipid-I (PGL-I) IgM antibodies among temporarily unfit blood donors at the Pará State Blood Bank (HEMOPA), located in the Amazon region of northern Brazil. Using an arbitrary high cutoff for optical density (OD ≥0.750) in ELISA, a subset of donors was invited for clinical evaluation for leprosy.

View Article and Find Full Text PDF

Glycosylation, the enzymatic addition of glycans to proteins and lipids, is a critical post-translational modification that influences protein folding, stability, trafficking, immune modulation, and cell signaling. The vast structural diversity of glycans arising from differences in monosaccharide composition, branching, and terminal modifications such as sialylation, fucosylation, and sulfation underpins their functional specificity and regulatory capacity. This review provides a comprehensive overview of glycan biosynthesis, with a focus on -glycans, -glycans, glycosaminoglycans (GAGs), and glycolipids.

View Article and Find Full Text PDF

Bacteria-Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy.

Adv Mater

August 2025

Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza, 50009, Spain.

Bacteria exhibit adaptive phenotypic traits that confer resistance to host defenses and antimicrobial therapies. In response to the global threat of antimicrobial resistance, bacteria-responsive nanostructured drug delivery systems have emerged as a promising alternative to conventional broad-spectrum antimicrobials. These systems release therapeutics selectively in response to bacterial presence or to their secreted enzymes, toxins, antigens, or extracellular biomarkers, enabling precise activation at infection sites while minimizing off-target effects.

View Article and Find Full Text PDF